Lineage Cell Therapeutics Raises $35.9 Million From Sales of Marketable Securities Holdings and an At-the-Market Equity Offering
Amount Raised
$35 Million
Round Type
Post-IPO Equity
CarlsbadManufacturingBiotechnologyTherapeuticsDescription
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that it raised $11 million in new capital from sales of its holdings of marketable securities, including shares of OncoCyte Corporation (Nasdaq: OCX) and Hadasit Bio-Holdings (TASE: HDST), as well as $25 million in gross proceeds from its at-the-market (“ATM”) offering. Lineage expects its approximately $57 million of cash and cash equivalents as of March 5, 2021 to fund operations well into 2023, by which time the Company expects to have achieved value-creating clinical and product development milestones. Lineage’s strengthened balance sheet also provides it with strategic flexibility in its ongoing partnership discussions.
Quick answer
Lineage Cell Therapeutics raised $35 Million in a Post-IPO Equity round, dated March 8, 2021. Lineage Cell Therapeutics is based in Carlsbad, California, United States.
- How much did Lineage Cell Therapeutics raise?
- Lineage Cell Therapeutics raised $35 Million in a Post-IPO Equity round on March 8, 2021.
- What does Lineage Cell Therapeutics do?
- Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel or 'off-the-shelf,' cell therapies to address unmet medical needs.
- Where is Lineage Cell Therapeutics based and how big is it?
- Lineage Cell Therapeutics is based in Carlsbad, California, United States. Fundz records about 70 employees.
- Who are the decision-makers at Lineage Cell Therapeutics?
- Fundz holds 5 contacts at Lineage Cell Therapeutics, including the Founder and CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Manufacturing around the same time
Companies in the same sectors as Lineage Cell Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Liquidia raised $22M on April 16, 2021.
- AbSci Corp raised $125M on March 30, 2021.
- Revelation Biosciences raised $4.4M (Series A) on April 22, 2021.
- RxMP Therapeutics raised $1M (Seed) on April 21, 2021.
- Ascendia Pharmaceuticals raised $5M on April 20, 2021.
- Janux Therapeutics raised $125M (Series B) on April 20, 2021.
Who to call at Lineage Cell Therapeutics, and when
A new round usually means Lineage Cell Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Lineage Cell Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Lineage Cell Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Lineage Cell Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Lineage Cell Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Lineage Cell Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.